☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Zevra Therapeutics
Zevra Therapeutics Resubmits Arimoclomol’s NDA to the US FDA for Treating Niemann-Pick disease Type C (NPC)
January 1, 2024
Zevra Therapeutics to Acquire Acer Therapeutics for ~$91M
September 1, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.
